Aveanna Healthcare Q3 2026: EPS Beats, Guidance Raised
As seen on the 24/7 Wall St. homepage on November 12, 2026.
Aveanna raised its full-year adjusted EBITDA target to more than $374 million from more than $365 million. Cost discipline and 10.2% growth in private duty hours drove the quarter.
Continue ReadingShow less
Aveanna Healthcare posted adjusted EPS of $0.23 for its fiscal third quarter of 2026, beating expectations. Revenue climbed 11.8% compared to the same quarter a year earlier.
Private Duty Services drove the quarter, with hours up 10.2%, while Home Health and Hospice and Medical Solutions also grew, making the gains broad-based across all three reporting segments.
Cost discipline amplified the top-line gains, with corporate expenses down 31% and Adjusted EBITDA margin expanding to 14.4%. Operating income and net income both rose sharply.
Sponsored
Management raised its full-year 2026 Adjusted EBITDA target to greater than $374 million and lifted the revenue outlook to greater than $2.695 billion, reinforcing its stated priority of deleveraging.
Investors will want to track how Aveanna navigates Medicaid changes under the One Big Beautiful Bill Act and reimbursement pressure from Medicare Advantage plan growth, both flagged by the company as material risks. A DOJ Antitrust Division grand jury subpoena related to nurse wages and hiring also remains an open item worth monitoring.
Mentioned: AVAH